The development of encapsulated cell technologies as therapies for neurological and sensory diseases

Journal of Controlled Release

Volumn 160, Issue 1, 2012, Pages 3-13

  Zanin, M P ^a   Pettingill, L N ^a   Harvey, A R ^b   Emerich, D F ^c   Thanos, C G ^d   Shepherd, R K ^a,e  

^a Bionics Institute   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NsGene Inc   (United States)

^d CytoSolv   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Encapsulation; Hearing loss; Neurotrophin; Parkinson's disease; Retinal degeneration

Indexed keywords

ALZHEIMER'S DISEASE; HEARING LOSS; NEUROTROPHINS; PARKINSON'S DISEASE; RETINAL DEGENERATIONS;

AUDITION; CELLS; CYTOLOGY; ENCAPSULATION; NEURODEGENERATIVE DISEASES; TISSUE;

DISEASE CONTROL;

ACRYLONITRILE VINYL CHLORIDE COPOLYMER; ALGINIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; COPOLYMER; FIBROBLAST GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1; LEVODOPA; MICROSPHERE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; OPIATE; POLYETHERSULFONE; POLYGLACTIN; POLYLYSINE; POLYORNITHINE; POLYPROPYLENE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CANCER PAIN; CELL ENCAPSULATION; CELL MEMBRANE PERMEABILITY; CHRONIC PAIN; COCHLEA PROSTHESIS; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DRUG DOSE INCREASE; EPILEPSY; HEARING LOSS; HOLLOW FIBER; HUMAN; HUNTINGTON CHOREA; IMPLANTATION; INSULIN RELEASE; MICROCAPSULE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; SENSORY DYSFUNCTION; STEM CELL TRANSPLANTATION; STROKE; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ANIMALS; CELL TRANSPLANTATION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANES, ARTIFICIAL; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; PERMEABILITY; SENSATION DISORDERS; TECHNOLOGY, PHARMACEUTICAL; TRANSPLANTATION IMMUNOLOGY;

EID: 84861527911     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.01.021     Document Type: Review

References (189)

1. F. Lim, and A.M. Sun Microencapsulated islets as bioartificial endocrine pancreas Science 210 1980 908 910
2. M. Barinaga Neurotrophic factors enter the clinic Science 264 1994 772 774
3. R.G. Miller, J.H. Petajan, W.W. Bryan, C. Armon, R.J. Barohn, J.C. Goodpasture, R.J. Hoagland, G.J. Parry, M.A. Ross, and S.C. Stromatt A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group Ann. Neurol. 39 1996 256 260
4. M.H. Tuszynski, L. Thal, M. Pay, D.P. Salmon, H.S. U, R. Bakay, P. Patel, A. Blesch, H.L. Vahlsing, G. Ho, G. Tong, S.G. Potkin, J. Fallon, L. Hansen, E.J. Mufson, J.H. Kordower, C. Gall, and J. Conner A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease Nat. Med. 11 2005 551 555
5. L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, and F. Collins GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 1993 1130 1132
6. P. Aebischer, M. Schluep, N. Deglon, J.M. Joseph, L. Hirt, B. Heyd, M. Goddard, J.P. Hammang, A.D. Zurn, A.C. Kato, F. Regli, and E.E. Baetge Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients Nat. Med. 2 1996 696 699
7. E. Buchser, M. Goddard, B. Heyd, J.M. Joseph, J. Favre, N. de Tribolet, M. Lysaght, and P. Aebischer Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience Anesthesiology 85 1996 1005 1012 discussion 1029A-1030A
8. E. Kovari, J. Horvath, and C. Bouras Neuropathology of Lewy body disorders Brain Res. Bull. 80 2009 203 210
9. G.C. O'Keeffe, A.W. Michell, and R.A. Barker Biomarkers in Huntington's and Parkinson's Disease Ann. N. Y. Acad. Sci. 1180 2009 97 110
10. J.H. Bower, D.M. Maraganore, S.K. McDonnell, and W.A. Rocca Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990 Neurology 52 1999 1214 1220
11. M.C. de Rijk, M.M. Breteler, G.A. Graveland, A. Ott, D.E. Grobbee, F.G. van der Meche, and A. Hofman Prevalence of Parkinson's disease in the elderly: the Rotterdam Study Neurology 45 1995 2143 2146
12. D.M. Huse, K. Schulman, L. Orsini, J. Castelli-Haley, S. Kennedy, and G. Lenhart Burden of illness in Parkinson's disease Mov. Disord. 20 2005 1449 1454
13. S. Fahn, D. Oakes, I. Shoulson, K. Kieburtz, A. Rudolph, A. Lang, C.W. Olanow, C. Tanner, and K. Marek Levodopa and the progression of Parkinson's disease N. Engl. J. Med. 351 2004 2498 2508
14. S. Fahn The spectrum of levodopa-induced dyskinesias Ann. Neurol. 47 2000 S2 S9 discussion S9-11
15. M.R. Luquin, O. Scipioni, J. Vaamonde, O. Gershanik, and J.A. Obeso Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification Mov. Disord. 7 1992 117 124
16. M.M. Mouradian, I.J. Heuser, F. Baronti, G. Fabbrini, J.L. Juncos, and T.N. Chase Pathogenesis of dyskinesias in Parkinson's disease Ann. Neurol. 25 1989 523 526
17. E.O. Backlund, P.O. Granberg, B. Hamberger, E. Knutsson, A. Martensson, G. Sedvall, A. Seiger, and L. Olson Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials J. Neurosurg. 62 1985 169 173
18. C.G. Goetz, C.W. Olanow, W.C. Koller, R.D. Penn, D. Cahill, R. Morantz, G. Stebbins, C.M. Tanner, H.L. Klawans, and K.M. Shannon Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease N. Engl. J. Med. 320 1989 337 341
19. I. Madrazo, R. Drucker-Colin, V. Diaz, J. Martinez-Mata, C. Torres, and J.J. Becerril Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease N. Engl. J. Med. 316 1987 831 834
20. C.G. Goetz, G.T. Stebbins III, H.L. Klawans, W.C. Koller, R.G. Grossman, R.A. Bakay, and R.D. Penn United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up Neurology 41 1991 1719 1722
21. P. Aebischer, P.A. Tresco, J. Sagen, and S.R. Winn Transplantation of microencapsulated bovine chromaffin cells reduces lesion-induced rotational asymmetry in rats Brain Res. 560 1991 43 49
22. I. Date, T. Shingo, T. Ohmoto, and D.F. Emerich Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells Exp. Neurol. 147 1997 10 17
23. S.R. Winn, P.A. Tresco, B. Zielinski, L.A. Greene, C.B. Jaeger, and P. Aebischer Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells Exp. Neurol. 113 1991 322 329
24. H.C. Hung, and E.H. Lee The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP + toxicity: role of BDNF gene expression Brain Res. Mol. Brain Res. 41 1996 14 26
25. R. Kohno, H. Sawada, Y. Kawamoto, K. Uemura, H. Shibasaki, and S. Shimohama BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line Biochem. Biophys. Res. Commun. 318 2004 113 118
26. M. Levivier, D.M. Gash, and S. Przedborski Time course of the neuroprotective effect of transplantation on quinolinic acid-induced lesions of the striatum Neuroscience 69 1995 43 50
27. M. Levivier, S. Przedborski, C. Bencsics, and U.J. Kang Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease J. Neurosci. 15 1995 7810 7820
28. M.G. Murer, Q. Yan, and R. Raisman-Vozari Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease Prog. Neurobiol. 63 2001 71 124
29. T. Tsukahara, M. Takeda, S. Shimohama, O. Ohara, and N. Hashimoto Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced parkinsonism in monkeys Neurosurgery 37 1995 733 739 discussion 739-741
30. C. Ericson, B. Georgievska, and C. Lundberg Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease Eur. J. Neurosci. 22 2005 2755 2764
31. J.H. Kordower, S. Palfi, E.Y. Chen, S.Y. Ma, T. Sendera, E.J. Cochran, E.J. Mufson, R. Penn, C.G. Goetz, and C.D. Comella Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease Ann. Neurol. 46 1999 419 424
32. J.G. Nutt, K.J. Burchiel, C.L. Comella, J. Jankovic, A.E. Lang, E.R. Laws Jr., A.M. Lozano, R.D. Penn, R.K. Simpson Jr., M. Stacy, and G.F. Wooten Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 2003 69 73
33. J.T. Slevin, D.M. Gash, C.D. Smith, G.A. Gerhardt, R. Kryscio, H. Chebrolu, A. Walton, R. Wagner, and A.B. Young Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal J. Neurosurg. 106 2007 614 620
34. N.K. Patel, M. Bunnage, P. Plaha, C.N. Svendsen, P. Heywood, and S.S. Gill Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study Ann. Neurol. 57 2005 298 302
35. S. Ramaswamy, K.E. Soderstrom, and J.H. Kordower Trophic factors therapy in Parkinson's disease Prog. Brain Res. 175 2009 201 216
36. T. Yasuhara, T. Shingo, K. Muraoka, K. Kobayashi, A. Takeuchi, A. Yano, Y. Wenji, M. Kameda, T. Matsui, Y. Miyoshi, and I. Date Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease J. Neurosurg. 102 2005 80 89
37. A. Sajadi, J.C. Bensadoun, B.L. Schneider, C. Lo Bianco, and P. Aebischer Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease Neurobiol. Dis. 22 2006 119 129
38. H. Kishima, T. Poyot, J. Bloch, J. Dauguet, F. Conde, F. Dolle, F. Hinnen, W. Pralong, S. Palfi, N. Deglon, P. Aebischer, and P. Hantraye Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons Neurobiol. Dis. 16 2004 428 439
39. J.L. Tseng, E.E. Baetge, A.D. Zurn, and P. Aebischer GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine J. Neurosci. 17 1997 325 333
40. J.L. Tseng, S.L. Bruhn, A.D. Zurn, and P. Aebischer Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy Neuroreport 9 1998 1817 1822
41. D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T.B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, N. Haase, S. Hailpern, M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. McDermott, J. Meigs, D. Mozaffarian, G. Nichol, C. O'Donnell, V. Roger, W. Rosamond, R. Sacco, P. Sorlie, R. Stafford, J. Steinberger, T. Thom, S. Wasserthiel-Smoller, N. Wong, J. Wylie-Rosett, and Y. Hong Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 2009 e21 e181
42. H.D. Muller, K.M. Hanumanthiah, K. Diederich, S. Schwab, W.R. Schabitz, and C. Sommer Brain-derived neurotrophic factor but not forced arm use improves long-term outcome after photothrombotic stroke and transiently upregulates binding densities of excitatory glutamate receptors in the rat brain Stroke 39 2008 1012 1021
43. W.R. Schabitz, C. Berger, R. Kollmar, M. Seitz, E. Tanay, M. Kiessling, S. Schwab, and C. Sommer Effect of brain-derived neurotrophic factor treatment and forced arm use on functional motor recovery after small cortical ischemia Stroke 35 2004 992 997
44. S. Katsuragi, T. Ikeda, I. Date, T. Shingo, T. Yasuhara, and T. Ikenoue Grafting of glial cell line-derived neurotrophic factor secreting cells for hypoxic-ischemic encephalopathy in neonatal rats Am. J. Obstet. Gynecol. 192 2005 1137 1145
45. S.J. Skinner, M.S. Geaney, H. Lin, M. Muzina, A.K. Anal, R.B. Elliott, and P.L. Tan Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma J. Neural Eng. 6 2009 065001
46. C.V. Borlongan, S.J. Skinner, M. Geaney, A.V. Vasconcellos, R.B. Elliott, and D.F. Emerich CNS grafts of rat choroid plexus protect against cerebral ischemia in adult rats Neuroreport 15 2004 1543 1547
47. C.V. Borlongan, S.J. Skinner, M. Geaney, A.V. Vasconcellos, R.B. Elliott, and D.F. Emerich Intracerebral transplantation of porcine choroid plexus provides structural and functional neuroprotection in a rodent model of stroke Stroke 35 2004 2206 2210
48. T. Perry, D.K. Lahiri, K. Sambamurti, D. Chen, M.P. Mattson, J.M. Egan, and N.H. Greig Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron J. Neurosci. Res. 72 2003 603 612
49. T. Perry, D.K. Lahiri, D. Chen, J. Zhou, K.T. Shaw, J.M. Egan, and N.H. Greig A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells J. Pharmacol. Exp. Ther. 300 2002 958 966
50. C.P. Gilman, T. Perry, K. Furukawa, N.H. Grieg, J.M. Egan, and M.P. Mattson Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons J. Neurochem. 87 2003 1137 1144
51. A.M. Heile, C. Wallrapp, P.M. Klinge, A. Samii, M. Kassem, G. Silverberg, and T. Brinker Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury Neurosci. Lett. 463 2009 176 181
52. T. Brinker GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage in: http://clinicaltrials.gov/ct2/ show/NCT01298830 2011
53. CellMed, CellBead Neuro, in: CellMed product candidates, CellMed, 2011.
54. WHO Neurological Disorders: Public Health Challenges, in, Geneva 2006
55. WHO Fact Sheet 999 - Epilepsy 2009
56. CDC Fast Facts: Epilepsy 2010
57. M. Privitera Current challenges in the management of epilepsy Am. J. Manag. Care 17 2011 S195 S203
58. S. Wiebe, W.T. Blume, J.P. Girvin, and M. Eliasziw A randomized, controlled trial of surgery for temporal-lobe epilepsy N. Engl. J. Med. 345 2001 311 318
59. S.D. Croll, C. Suri, D.L. Compton, M.V. Simmons, G.D. Yancopoulos, R.M. Lindsay, S.J. Wiegand, J.S. Rudge, and H.E. Scharfman Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex Neuroscience 93 1999 1491 1506
60. I. Kanter-Schlifke, L. Fjord-Larsen, P. Kusk, M. Angehagen, L. Wahlberg, and M. Kokaia GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus Exp. Neurol. 216 2009 413 419
61. S. Kuramoto, T. Yasuhara, T. Agari, A. Kondo, M. Jing, Y. Kikuchi, A. Shinko, T. Wakamori, M. Kameda, F. Wang, K. Kin, S. Edahiro, Y. Miyoshi, and I. Date BDNF-secreting capsule exerts neuroprotective effects on epilepsy model of rats Brain Res 1368 2011 281 289
62. S. Reibel, Y. Larmet, B.T. Le, J. Carnahan, C. Marescaux, and A. Depaulis Brain-derived neurotrophic factor delays hippocampal kindling in the rat Neuroscience 100 2000 777 788
63. H.E. Scharfman, A.L. Sollas, K.L. Smith, M.B. Jackson, and J.H. Goodman Structural and functional asymmetry in the normal and epileptic rat dentate gyrus J. Comp. Neurol. 454 2002 424 439
64. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group Cell 72 1993 971 983
65. J.P. Vonsattel, and M. DiFiglia Huntington disease J. Neuropathol. Exp. Neurol. 57 1998 369 384
66. J.P. Vonsattel, R.H. Myers, T.J. Stevens, R.J. Ferrante, E.D. Bird, and E.P. Richardson Jr. Neuropathological classification of Huntington's disease J. Neuropathol. Exp. Neurol. 44 1985 559 577
67. H.D. Rosas, W.J. Koroshetz, Y.I. Chen, C. Skeuse, M. Vangel, M.E. Cudkowicz, K. Caplan, K. Marek, L.J. Seidman, N. Makris, B.G. Jenkins, and J.M. Goldstein Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis Neurology 60 2003 1615 1620
68. F.O. Walker Huntington's disease Lancet 369 2007 218 228
69. A. Weiss, D. Abramowski, M. Bibel, R. Bodner, V. Chopra, M. DiFiglia, J. Fox, K. Kegel, C. Klein, S. Grueninger, S. Hersch, D. Housman, E. Regulier, H.D. Rosas, M. Stefani, S. Zeitlin, G. Bilbe, and P. Paganetti Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease Anal. Biochem. 395 2009 8 15
70. D.M. Araujo, and D.C. Hilt Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease Neuroscience 81 1997 1099 1110
71. D.M. Araujo, and D.C. Hilt Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid Neuroscience 82 1998 117 127
72. S.W. Davies, and K. Beardsall Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones Neurosci. Lett. 140 1992 161 164
73. D.F. Emerich, M.D. Lindner, S.R. Winn, E.Y. Chen, B.R. Frydel, and J.H. Kordower Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease J. Neurosci. 16 1996 5168 5181
74. D.F. Emerich, S.R. Winn, P.M. Hantraye, M. Peschanski, E.Y. Chen, Y. Chu, P. McDermott, E.E. Baetge, and J.H. Kordower Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease Nature 386 1997 395 399
75. E. Gratacos, E. Perez-Navarro, E. Tolosa, E. Arenas, and J. Alberch Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members J. Neurochem. 78 2001 1287 1296
76. P. Menei, J.M. Pean, V. Nerriere-Daguin, C. Jollivet, P. Brachet, and J.P. Benoit Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage Exp. Neurol. 161 2000 259 272
77. V. Mittoux, J.M. Joseph, F. Conde, S. Palfi, C. Dautry, T. Poyot, J. Bloch, N. Deglon, S. Ouary, E.A. Nimchinsky, E. Brouillet, P.R. Hof, M. Peschanski, P. Aebischer, and P. Hantraye Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease Hum. Gene Ther. 11 2000 1177 1187
78. E. Perez-Navarro, J. Alberch, I. Neveu, and E. Arenas Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo Neuroscience 91 1999 1257 1264
79. E. Perez-Navarro, A.M. Canudas, P. Akerund, J. Alberch, and E. Arenas Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease J. Neurochem. 75 2000 2190 2199
80. Y. Miyoshi, I. Date, T. Ohmoto, and H. Iwata Histological analysis of microencapsulated dopamine-secreting cells in agarose/poly(styrene sulfonic acid) mixed gel xenotransplanted into the brain Exp. Neurol. 138 1996 169 175
81. J.H. Kordower, S.R. Winn, Y.T. Liu, E.J. Mufson, J.R. Sladek Jr., J.P. Hammang, E.E. Baetge, and D.F. Emerich The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor Proc. Natl. Acad. Sci. U. S. A. 91 1994 10898 10902
82. J. Bloch, A.C. Bachoud-Levi, N. Deglon, J.P. Lefaucheur, L. Winkel, S. Palfi, J.P. Nguyen, C. Bourdet, V. Gaura, P. Remy, P. Brugieres, M.F. Boisse, S. Baudic, P. Cesaro, P. Hantraye, P. Aebischer, and M. Peschanski Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study Hum. Gene Ther. 15 2004 968 975
83. D.F. Emerich, C.G. Thanos, M. Goddard, S.J. Skinner, M.S. Geany, W.J. Bell, B. Bintz, P. Schneider, Y. Chu, R.S. Babu, C.V. Borlongan, K. Boekelheide, S. Hall, B. Bryant, and J.H. Kordower Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys Neurobiol. Dis. 23 2006 471 480
84. D.F. Emerich, and C.V. Borlongan Potential of choroid plexus epithelial cell grafts for neuroprotection in Huntington's disease: what remains before considering clinical trials Neurotox. Res. 15 2009 205 211
85. C.V. Borlongan, C.G. Thanos, S.J. Skinner, M. Geaney, and D.F. Emerich Transplants of encapsulated rat choroid plexus cells exert neuroprotection in a rodent model of Huntington's disease Cell Transplant. 16 2008 987 992
86. D.F. Emerich, and C.G. Thanos In vitro culture duration does not impact the ability of encapsulated choroid plexus transplants to prevent neurological deficits in an excitotoxin-lesioned rat model of Huntington's disease Cell Transplant. 15 2006 595 602
87. A. Lobo, L.J. Launer, L. Fratiglioni, K. Andersen, A. Di Carlo, M.M. Breteler, J.R. Copeland, J.F. Dartigues, C. Jagger, J. Martinez-Lage, H. Soininen, and A. Hofman Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group Neurology 54 2000 S4 S9
88. B.L. Plassman, K.M. Langa, G.G. Fisher, S.G. Heeringa, D.R. Weir, M.B. Ofstedal, J.R. Burke, M.D. Hurd, G.G. Potter, W.L. Rodgers, D.C. Steffens, R.J. Willis, and R.B. Wallace Prevalence of dementia in the United States: the aging, demographics, and memory study Neuroepidemiology 29 2007 125 132
89. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H.M. Arrighi Forecasting the global burden of Alzheimer's disease Alzheimers Dement. 3 2007 186 191
90. A.s. Association Alzheimer's Disease Facts and Figures, in, Chicago, IL 2010
91. C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, and E. Jones Alzheimer's disease Lancet 377 2011 1019 1031
92. D.J. Selkoe Alzheimer's disease is a synaptic failure Science 298 2002 789 791
93. H.W. Querfurth, and F.M. LaFerla Alzheimer's disease N. Engl. J. Med. 362 2010 329 344
94. M.G. Murer, F. Boissiere, Q. Yan, S. Hunot, J. Villares, B. Faucheux, Y. Agid, E. Hirsch, and R. Raisman-Vozari An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease Neuroscience 88 1999 1015 1032
95. H.S. Phillips, J.M. Hains, M. Armanini, G.R. Laramee, S.A. Johnson, and J.W. Winslow BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease Neuron 7 1991 695 702
96. S. Ando, S. Kobayashi, H. Waki, K. Kon, F. Fukui, T. Tadenuma, M. Iwamoto, Y. Takeda, N. Izumiyama, K. Watanabe, and H. Nakamura Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine J. Neurosci. Res. 70 2002 519 527
97. A.H. Nagahara, D.A. Merrill, G. Coppola, S. Tsukada, B.E. Schroeder, G.M. Shaked, L. Wang, A. Blesch, A. Kim, J.M. Conner, E. Rockenstein, M.V. Chao, E.H. Koo, D. Geschwind, E. Masliah, A.A. Chiba, and M.H. Tuszynski Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease Nat. Med. 15 2009 331 337
98. P. Garcia, I. Youssef, J.K. Utvik, S. Florent-Bechard, V. Barthelemy, C. Malaplate-Armand, B. Kriem, C. Stenger, V. Koziel, J.L. Olivier, M.C. Escanye, M. Hanse, A. Allouche, C. Desbene, F.T. Yen, R. Bjerkvig, T. Oster, S.P. Niclou, and T. Pillot Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease J. Neurosci. 30 2010 7516 7527
99. T. Perry, and N.H. Greig The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease J. Alzheimers Dis. 4 2002 487 496
100. P.M. Klinge, K. Harmening, M.C. Miller, A. Heile, C. Wallrapp, P. Geigle, and T. Brinker Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease Neurosci. Lett. 497 2011 6 10
101. V.E. Koliatsos, H.J. Nauta, R.E. Clatterbuck, D.M. Holtzman, W.C. Mobley, and D.L. Price Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey J. Neurosci. 10 1990 3801 3813
102. M.H. Tuszynski, H. Sang, K. Yoshida, and F.H. Gage Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain Ann. Neurol. 30 1991 625 636
103. W. Fischer, K. Wictorin, A. Bjorklund, L.R. Williams, S. Varon, and F.H. Gage Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor Nature 329 1987 65 68
104. D.F. Emerich, J.P. Hammang, E.E. Baetge, and S.R. Winn Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum Exp. Neurol. 130 1994 141 150
105. D.F. Emerich, S.R. Winn, J. Harper, J.P. Hammang, E.E. Baetge, and J.H. Kordower Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons J. Comp. Neurol. 349 1994 148 164
106. S.R. Winn, J.P. Hammang, D.F. Emerich, A. Lee, R.D. Palmiter, and E.E. Baetge Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons Proc. Natl. Acad. Sci. U. S. A. 91 1994 2324 2328
107. S.R. Winn, M.D. Lindner, A. Lee, G. Haggett, J.M. Francis, and D.F. Emerich Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences Exp. Neurol. 140 1996 126 138
108. M. Jönhagen Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer's Disease Patients (NsG0202) in: http://clinicaltrials.gov/ct2/show/ NCT01163825 2010
109. nsgene, NsG0202 - EC Biodelivery for Alzheimer's disease, in: nsgene product candidates, nsgene, Ballerup, 2011.
110. G. Logroscino, B.J. Traynor, O. Hardiman, A. Chio, P. Couratier, J.D. Mitchell, R.J. Swingler, and E. Beghi Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues J. Neurol. Neurosurg. Psychiatry 79 2008 6 11
111. D.R. Rosen, T. Siddique, D. Patterson, D.A. Figlewicz, P. Sapp, A. Hentati, D. Donaldson, J. Goto, J.P. O'Regan, H.X. Deng, Z. Rahmani, A. Krizus, D. McKenna-Yasek, A. Cayabyab, S.M. Gaston, R. Berger, R.E. Tanzi, J.J. Halperin, B. Herzfeldt, R. Van den Bergh, W-Y. Hung, T. Bird, G. Deng, D.W. Mulder, C. Smyth, N.G. Laing, E. Soriano, M.A. Pericak -Vance, J. Haines, G.A. Rouleau, J.S. Gusella, H.R. Horvitz, R.H. Brown Jr., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature 362 (1993) 59-62.
112. H. Mitsumoto, K. Ikeda, B. Klinkosz, J.M. Cedarbaum, V. Wong, and R.M. Lindsay Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF Science 265 1994 1107 1110
113. M. Sendtner, H. Schmalbruch, K.A. Stockli, P. Carroll, G.W. Kreutzberg, and H. Thoenen Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy Nature 358 1992 502 504
114. S.A. Tan, N. Deglon, A.D. Zurn, E.E. Baetge, B. Bamber, A.C. Kato, and P. Aebischer Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF Cell Transplant. 5 1996 577 587
115. Y. Sagot, S.A. Tan, E. Baetge, H. Schmalbruch, A.C. Kato, and P. Aebischer Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse Eur. J. Neurosci. 7 1995 1313 1322
116. N. Deglon, B. Heyd, S.A. Tan, J.M. Joseph, A.D. Zurn, and P. Aebischer Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts Hum. Gene Ther. 7 1996 2135 2146
117. M.H. Mohajeri, D.A. Figlewicz, and M.C. Bohn Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis Hum. Gene Ther. 10 1999 1853 1866
118. M. Suzuki, J. McHugh, C. Tork, B. Shelley, A. Hayes, I. Bellantuono, P. Aebischer, and C.N. Svendsen Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS Mol. Ther. 16 2008 2002 2010
119. C. Zheng, I. Nennesmo, B. Fadeel, and J.I. Henter Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS Ann. Neurol. 56 2004 564 567
120. B. Oosthuyse, L. Moons, E. Storkebaum, H. Beck, D. Nuyens, K. Brusselmans, J. Van Dorpe, P. Hellings, M. Gorselink, S. Heymans, G. Theilmeier, M. Dewerchin, V. Laudenbach, P. Vermylen, H. Raat, T. Acker, V. Vleminckx, L. Van Den Bosch, N. Cashman, H. Fujisawa, M.R. Drost, R. Sciot, F. Bruyninckx, D.J. Hicklin, C. Ince, P. Gressens, F. Lupu, K.H. Plate, W. Robberecht, J.M. Herbert, D. Collen, and P. Carmeliet Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration Nat. Genet. 28 2001 131 138
121. E. Storkebaum, D. Lambrechts, M. Dewerchin, M.P. Moreno-Murciano, S. Appelmans, H. Oh, P. Van Damme, B. Rutten, W.Y. Man, M. De Mol, S. Wyns, D. Manka, K. Vermeulen, L. Van Den Bosch, N. Mertens, C. Schmitz, W. Robberecht, E.M. Conway, D. Collen, L. Moons, and P. Carmeliet Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS Nat. Neurosci. 8 2005 85 92
122. W. Robberecht A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis in: http://clinicaltrials.gov/ct2/show/NCT00800501 2008
123. W. Robberecht An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis in: http://clinicaltrials.gov/ct2/show/NCT01384162 2011
124. C. Committee on Advancing Pain Research, and Education Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research 2011 The National Academies Press Washington DC
125. R. Benyamin, A.M. Trescot, S. Datta, R. Buenaventura, R. Adlaka, N. Sehgal, S.E. Glaser, and R. Vallejo Opioid complications and side effects Pain Physician 11 2008 S105 S120
126. H.G. Birnbaum, A.G. White, J.L. Reynolds, P.E. Greenberg, M. Zhang, S. Vallow, J.R. Schein, and N.P. Katz Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective Clin. J. Pain 22 2006 667 676
127. K. Unsicker The trophic cocktail made by adrenal chromaffin cells Exp. Neurol. 123 1993 167 173
128. J.A. Siuciak, C.A. Altar, S.J. Wiegand, and R.M. Lindsay Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3 Brain Res. 633 1994 326 330
129. J. Sagen, G.D. Pappas, and H.B. Pollard Analgesia induced by isolated bovine chromaffin cells implanted in rat spinal cord Proc. Natl. Acad. Sci. U. S. A. 83 1986 7522 7526
130. A.T. Hama, and J. Sagen Alleviation of neuropathic pain symptoms by xenogeneic chromaffin cell grafts in the spinal subarachnoid space Brain Res. 651 1994 183 193
131. J. Sagen, H. Wang, and G.D. Pappas Adrenal medullary implants in the rat spinal cord reduce nociception in a chronic pain model Pain 42 1990 69 79
132. W. Yu, J.X. Hao, X.J. Xu, J. Saydoff, A. Haegerstrand, T. Hokfelt, and Z. Wiesenfeld-Hallin Long-term alleviation of allodynia-like behaviors by intrathecal implantation of bovine chromaffin cells in rats with spinal cord injury Pain 74 1998 115 122
133. J. Sagen, H. Wang, P.A. Tresco, and P. Aebischer Transplants of immunologically isolated xenogeneic chromaffin cells provide a long-term source of pain-reducing neuroactive substances J. Neurosci. 13 1993 2415 2423
134. Y. Jeon, K. Kwak, S. Kim, Y. Kim, J. Lim, and W. Baek Intrathecal implants of microencapsulated xenogenic chromaffin cells provide a long-term source of analgesic substances Transplant. Proc. 38 2006 3061 3065
135. Y.M. Kim, K.H. Kwak, J.O. Lim, and W.Y. Baek Reduction of allodynia by intrathecal transplantation of microencapsulated porcine chromaffin cells Artif. Organs 33 2009 240 249
136. S. Wu, C. Ma, G. Li, M. Mai, and Y. Wu Intrathecal implantation of microencapsulated PC12 cells reduces cold allodynia in a rat model of neuropathic pain Artif. Organs 35 2011 294 300
137. Y. Lazorthes, J. Sagen, B. Sallerin, J. Tkaczuk, H. Duplan, J.C. Sol, M. Tafani, and J.C. Bes Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study Pain 87 2000 19 32
138. S. Kochkin The Impact of Untreated Hearing Loss on Household Income 2005 Better Hearing Institute
139. N.A. Hardie, and R.K. Shepherd Sensorineural hearing loss during development: morphological and physiological response of the cochlea and auditory brainstem Hear. Res. 128 1999 147 165
140. J. Otte, H.F. Schunknecht, and A.G. Kerr Ganglion cell populations in normal and pathological human cochleae. Implications for cochlear implantation Laryngoscope 88 1978 1231 1246
141. B.J. Gantz, G.G. Woodworth, J.F. Knutson, P.J. Abbas, and R.S. Tyler Multivariate predictors of audiological success with multichannel cochlear implants Ann. Otol. Rhinol. Laryngol. 102 1993 909 916
142. J.B. Nadol Jr., Y.S. Young, and R.J. Glynn Survival of spiral ganglion cells in profound sensorineural hearing loss: implications for cochlear implantation Ann. Otol. Rhinol. Laryngol. 98 1989 411 416
143. R.K. Shepherd, L.A. Roberts, and A.G. Paolini Long-term sensorineural hearing loss induces functional changes in the rat auditory nerve Eur. J.
144. L.C. Schecterson, and M. Bothwell Neurotrophin and neurotrophin receptor mRNA expression in developing inner ear Hear. Res. 73 1994 92 100
145. K. Stankovic, C. Rio, A. Xia, M. Sugawara, J.C. Adams, M.C. Liberman, and G. Corfas Survival of adult spiral ganglion neurons requires erbB receptor signaling in the inner ear J. Neurosci. 24 2004 8651 8661
146. J. Tan, and R.K. Shepherd Aminoglycoside-induced degeneration of adult spiral ganglion neurons involves differential modulation of tyrosine kinase B and p75 neurotrophin receptor signaling Am. J. Pathol. 169 2006 528 543
147. J. Ylikoski, U. Pirvola, M. Moshnyakov, J. Palgi, U. Arumae, and M. Saarma Expression patterns of neurotrophin and their receptor mRNAs in the rat inner ear Hear. Res. 65 1993 69 78
148. L.N. Gillespie, G.M. Clark, P.F. Bartlett, and P.L. Marzella BDNF-induced survival of auditory neurons in vivo: cessation of treatment leads to accelerated loss of survival effects J. Neurosci. Res. 71 2003 785 790
149. L.N. Gillespie, G.M. Clark, and P.L. Marzella Delayed neurotrophin treatment supports auditory neuron survival in deaf guinea pigs Neuroreport 15 2004 1121 1125
150. R.K. Shepherd, A. Coco, S.B. Epp, and J.M. Crook Chronic depolarization enhances the trophic effects of brain-derived neurotrophic factor in rescuing auditory neurons following a sensorineural hearing loss J. Comp. Neurol. 486 2005 145 158
151. A.K. Wise, R. Richardson, J. Hardman, G. Clark, and S. O'Leary Resprouting and survival of guinea pig cochlear neurons in response to the administration of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 J. Comp. Neurol. 487 2005 147 165
152. R.K. Shepherd, A. Coco, and S.B. Epp Neurotrophins and electrical stimulation for protection and repair of spiral ganglion neurons following sensorineural hearing loss Hear. Res. 242 2008 100 109
153. L.N. Pettingill, R.L. Minter, and R.K. Shepherd Schwann cells genetically modified to express neurotrophins promote spiral ganglion neuron survival in vitro Neuroscience 152 2008 821 828
154. L.N. Pettingill, A. Wise, M.S. Geaney, and R.K. Shepherd Enhanced auditory neuron survival following cell-based BDNF treatment in the deaf guinea pig PLoS One 6 2011 e18733
155. A.K. Wise, J.B. Fallon, A.J. Neil, L.N. Pettingill, M.S. Geaney, S.J. Skinner, R.K. Shepherd, Combining cell-based therapies and neural prostheses to promote neural survival, Neurotherapeutics 8 (2011) 774-787.
156. D. Rejali, V.A. Lee, K.A. Abrashkin, N. Humayun, D.L. Swiderski, and Y. Raphael Cochlear implants and ex vivo BDNF gene therapy protect spiral ganglion neurons Hear. Res. 228 2007 180 187
157. D.B. Rein, P. Zhang, K.E. Wirth, P.P. Lee, T.J. Hoerger, N. McCall, R. Klein, J.M. Tielsch, S. Vijan, and J. Saaddine The economic burden of major adult visual disorders in the United States Arch. Ophthalmol. 124 2006 1754 1760
158. K.M. Gehrs, D.H. Anderson, L.V. Johnson, and G.S. Hageman Age-related macular degeneration - emerging pathogenetic and therapeutic concepts Ann. Med. 38 2006 450 471
159. A.F. Wright, C.F. Chakarova, M.M. Abd El-Aziz, and S.S. Bhattacharya Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait Nat. Rev. Genet. 11 2010 273 284
160. A.V. Chappelow, and P.K. Kaiser Neovascular age-related macular degeneration: potential therapies Drugs 68 2008 1029 1036
161. R.D. Jager, W.F. Mieler, and J.W. Miller Age-related macular degeneration N. Engl. J. Med. 358 2008 2606 2617
162. B.W. Jones, and R.E. Marc Retinal remodeling during retinal degeneration Exp. Eye Res. 81 2005 123 137
163. R.H. Guymer Managing neovascular age-related macular degeneration: a step into the light Med. J. Aust. 186 2007 276 277
164. K. Shintani, D.L. Shechtman, and A.S. Gurwood Review and update: current treatment trends for patients with retinitis pigmentosa Optometry 80 2009 384 401
165. N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
166. D.M. Brown, P.K. Kaiser, M. Michels, G. Soubrane, J.S. Heier, R.Y. Kim, J.P. Sy, and S. Schneider Ranibizumab versus verteporfin for neovascular age-related macular degeneration N. Engl. J. Med. 355 2006 1432 1444
167. J.C. Folk, and E.M. Stone Ranibizumab therapy for neovascular age-related macular degeneration N. Engl. J. Med. 363 2010 1648 1655
168. P.J. Rosenfeld, D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, C.Y. Chung, and R.Y. Kim Ranibizumab for neovascular age-related macular degeneration N. Engl. J. Med. 355 2006 1419 1431
169. N.H. Chong, R.A. Alexander, L. Waters, K.C. Barnett, A.C. Bird, and P.J. Luthert Repeated injections of a ciliary neurotrophic factor analogue leading to long-term photoreceptor survival in hereditary retinal degeneration Invest. Ophthalmol. Vis. Sci. 40 1999 1298 1305
170. M.M. LaVail, K. Unoki, D. Yasumura, M.T. Matthes, G.D. Yancopoulos, and R.H. Steinberg Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light Proc. Natl. Acad. Sci. U. S. A. 89 1992 11249 11253
171. M.M. LaVail, D. Yasumura, M.T. Matthes, C. Lau-Villacorta, K. Unoki, C.H. Sung, and R.H. Steinberg Protection of mouse photoreceptors by survival factors in retinal degenerations Invest. Ophthalmol. Vis. Sci. 39 1998 592 602
172. Q. Cui, Q. Lu, K.F. So, and H.K. Yip CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters Invest. Ophthalmol. Vis. Sci. 40 1999 760 766
173. E. Strettoi, and V. Pignatelli Modifications of retinal neurons in a mouse model of retinitis pigmentosa Proc. Natl. Acad. Sci. U. S. A. 97 2000 11020 11025
174. E. Strettoi, V. Porciatti, B. Falsini, V. Pignatelli, and C. Rossi Morphological and functional abnormalities in the inner retina of the rd/rd mouse J. Neurosci. 22 2002 5492 5504
175. Q. Cui, and A.R. Harvey CNTF promotes the regrowth of retinal ganglion cell axons into murine peripheral nerve grafts Neuroreport 11 2000 3999 4002
176. A.R. Harvey, Y. Hu, S.G. Leaver, C.B. Mellough, K. Park, J. Verhaagen, G.W. Plant, and Q. Cui Gene therapy and transplantation in CNS repair: the visual system Prog. Retin. Eye Res. 25 2006 449 489
177. D.F. Emerich, and C.G. Thanos NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells Curr. Opin. Mol. Ther. 10 2008 506 515
178. W. Tao, R. Wen, M.B. Goddard, S.D. Sherman, P.J. O'Rourke, P.F. Stabila, W.J. Bell, B.J. Dean, K.A. Kauper, V.A. Budz, W.G. Tsiaras, G.M. Acland, S. Pearce-Kelling, A.M. Laties, and G.D. Aguirre Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa Invest. Ophthalmol. Vis. Sci. 43 2002 3292 3298
179. C.G. Thanos, W.J. Bell, P. O'Rourke, K. Kauper, S. Sherman, P. Stabila, and W. Tao Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device Tissue Eng. 10 2004 1617 1622
180. P.A. Sieving, R.C. Caruso, W. Tao, H.R. Coleman, D.J. Thompson, K.R. Fullmer, and R.A. Bush Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants Proc. Natl. Acad. Sci. U. S. A. 103 2006 3896 3901
181. W. Tao A study of an Encapsulated Cell Technology (ECT) implant for patients with atrophic macular degeneration in: http://clinicaltrials.gov/ct2/ show/NCT00447954 2007
182. W. Tao A study of Encapsulated Cell Technology (ECT) implant for participants with early stage retinitis pigmentosa in: http://clinicaltrials. gov/ct2/show/NCT00447980 2007
183. M. Menard, J. Dusseault, G. Langlois, W.E. Baille, S.K. Tam, L. Yahia, X.X. Zhu, and J.P. Halle Role of protein contaminants in the immunogenicity of alginates J. Biomed. Mater. Res. B Appl. Biomater. 93 2010 333 340
184. G. Skjak-Braek, E. Murano, and S. Paoletti Alginate as immobilization material. II: determination of polyphenol contaminants by fluorescence spectroscopy, and evaluation of methods for their removal Biotechnol. Bioeng. 33 1989 90 94
185. M. Lohr, Z.T. Bago, H. Bergmeister, M. Ceijna, M. Freund, W. Gelbmann, W.H. Gunzburg, R. Jesnowski, J. Hain, K. Hauenstein, W. Henninger, A. Hoffmeyer, P. Karle, J.C. Kroger, G. Kundt, S. Liebe, U. Losert, P. Muller, A. Probst, K. Puschel, M. Renner, R. Renz, R. Saller, B. Salmons, and I. Walter Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study J. Mol. Med. 77 1999 393 398
186. M. Lohr, A. Hoffmeyer, J. Kroger, M. Freund, J. Hain, A. Holle, P. Karle, W.T. Knofel, S. Liebe, P. Muller, H. Nizze, M. Renner, R.M. Saller, T. Wagner, K. Hauenstein, W.H. Gunzburg, and B. Salmons Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma Lancet 357 2001 1591 1592
187. B. Salmons, E.M. Brandtner, K. Hettrich, W. Wagenknecht, B. Volkert, S. Fischer, J.A. Dangerfield, and W.H. Gunzburg Encapsulated cells to focus the metabolic activation of anticancer drugs Curr. Opin. Mol. Ther. 12 2010 450 460
188. B. Salmons, O. Hauser, W.H. Gunzburg, and W. Tabotta GMP production of an encapsulated cell therapy product: issues and considerations Bioprocess. J. 6 2007 37 44
189. P. Aebischer, and J. Ridet Recombinant proteins for neurodegenerative diseases: the delivery issue Trends Neurosci. 24 2001 533 540